Drugs / TURKOVAC
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT06997653 | Jan 2024 | COVID-19 | Health Institutes of Turkey | Withdrawn | No outcome recorded |
| Phase 2 | NCT05230940 | Feb 2022 → May 2023 | COVID-19 | Health Institutes of Turkey | Completed | No outcome recorded |
| Phase 2 | NCT04979949 | Jul 2021 → Mar 2022 | COVID-19 | Health Institutes of Turkey | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05077176 | Oct 2021 → May 2023 | COVID-19 | Health Institutes of Turkey | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05035238 Comparator | Oct 2021 | COVID-19 | Health Institutes of Turkey | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TURKOVAC | “This is a double-blind, triple dose, parallel, randomized design study comparing two different dose levels and immunization regimen of a novel COVID-19 vaccine candidate -...” NCT05035238 ↗5“TURKOVAC vaccines used as a booster dose” PMID 36315843 ↗ Oct 2022 “Biological: Turkovac” NCT05077176 ↗ |
| Known as | TURKOVAC Inactive | “Evaluation of the Efficacy, Safety and Immunogenicity of Inactivated COVID 19 Vaccine (TURKOVAC Inactive) in Healthy Population of 18 and 64 Years of Age (Both Inclusive): a...” NCT05035238 ↗ |
| Modality | Vaccine | “inactivated COVID 19 Vaccine- TURKOVAC” NCT05035238 ↗ |